10-Q: BioAffinity Technologies Q3 Loss Widens Amid Strategic Shift

BioAffinity Technologies reported a widened net loss of $5.1 million in Q3 2025, despite an 86% increase in CyPath Lung revenue, as it navigates strategic shifts and capital raises.

Summary

• Net loss for the nine months ended September 30, 2025, was $11.8 million, compared to $6.1 million for the same period in 2024.
• Consolidated net revenue decreased by 36% to $4.6 million for the nine months ended September 30, 2025, from $7.2 million in 2024, primarily due to discontinuing unprofitable pathology services.
• CyPath Lung testing revenue increased by 86% to $619,000 for the nine months ended September 30, 2025, with 775 tests delivered, up from $332,000 and 393 tests in 2024.
• The company raised approximately $10.4 million in gross proceeds from equity transactions during Q3 2025.
• Cash and cash equivalents stood at $7.7 million as of September 30, 2025, and $8.4 million as of October 29, 2025, expected to fund operations through May 2026.
• The company successfully regained compliance with Nasdaq's Minimum Bid Price and Minimum Stockholders Equity Rules as of October 14, 2025, but is subject to a one-year monitoring period.

Sentiment

Score: 4

Explanation: While CyPath Lung sales show strong growth and the company successfully addressed Nasdaq compliance, the significant increase in net loss, overall revenue decline, and explicit 'going concern' warning indicate substantial financial challenges and high risk. The capital raises are positive for liquidity but also highlight ongoing funding needs.

Positives

• CyPath Lung testing revenue increased by 86% to $619,000 for the nine months ended September 30, 2025, compared to $332,000 for the same period in 2024.
• CyPath Lung sales volume reached a record high in Q3 2025, increasing 95% over the prior quarter, driven by growing adoption from Veterans hospitals and mid-Atlantic market expansion.
• October 2025 CyPath Lung tests processed showed a 111% increase over the monthly average for the first nine months of 2025.
• Successfully raised approximately $10.4 million in gross proceeds from equity transactions during Q3 2025, significantly improving cash position.
• Received a notice of allowance from the U.S. Patent Office for its diagnostic algorithm and test method to detect lung cancer.
• The Australian Patent Office accepted a patent application for the company's proprietary platform technology for assessing lung health.
• Successfully regained compliance with Nasdaq's Minimum Bid Price Rule and Minimum Stockholders Equity Rule as of October 14, 2025.
• Appointed two new Board members, Roberto Rios, CPA, and John J. Oppenheimer, M.D., bringing expertise in corporate finance, biotechnology, medical devices, and lung health.

Negatives

• Net loss for the nine months ended September 30, 2025, widened to $11.8 million from $6.1 million in the prior year.
• Consolidated net revenue decreased by 36% to $4.6 million for the nine months ended September 30, 2025, from $7.2 million in 2024, primarily due to discontinuing unprofitable pathology services.
• Accumulated deficit reached $65.4 million as of September 30, 2025.
• Net cash used in operating activities increased to $6.8 million for the nine months ended September 30, 2025, from $5.6 million in 2024.
• The company's independent registered public accounting firm included an explanatory paragraph in its opinion regarding substantial doubt about the company's ability to continue as a going concern.
• The company was at risk of delisting from Nasdaq due to non-compliance with minimum bid price and stockholders' equity requirements, though compliance was later regained.

Risks

• Substantial doubt about the ability to continue as a going concern for at least one year due to significant losses and negative cash flows.
• Reliance on obtaining additional capital and financing; insufficient funding may lead to curtailment or cessation of operations.
• Uncertainty in generating significant profit from PPLS services and accurately estimating future expenses.
• Risk of not maintaining compliance with Nasdaq's continued listing requirements, which could lead to delisting and adverse effects on liquidity and capital raising.
• Dependence on third parties for clinical trials.
• Ability to obtain necessary regulatory approvals for diagnostic tests or therapeutic product candidates.
• Potential for pre-clinical and clinical trials to indicate products are unsafe or ineffective.
• Ability to obtain and maintain intellectual property protection and incur substantial costs from IP lawsuits.
• Competition from existing and future therapies and diagnostic tests.
• Ability to expand organization and retain/attract key personnel.
• Potential for product liability lawsuits.
• Market acceptance of diagnostic tests and therapeutic product candidates.
• Compliance with government regulations.
• Impact of health epidemics, economic instability, inflationary pressures, increased interest rates, economic slowdown, and geopolitical tensions.

Future Outlook

The company anticipates its current cash resources will support operations through May 2026. It expects to continue incurring significant operating losses and negative cash flows for the foreseeable future as it advances diagnostic tests through clinical trials and expands commercialization efforts. The company plans to raise additional capital through equity or debt securities, strategic relationships, or grants to fund future operations and product development. It also intends to present and publish research findings for its therapeutic discoveries and seek strategic partners for their development.

Management Comments

• Management concludes that there is substantial doubt about the Company's ability to continue as a going concern for a period of at least twelve (12) months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements.
• Without funding from the proceeds of a capital raise or strategic relationship or grant, management anticipates that the Company's current cash resources are sufficient to continue operations through May 2026.
• CyPath Lung testing revenue increased approximately 86%... due to an increase in total test results delivered to 775 for the nine months ended September 30, 2025.
• Sales of CyPath Lung reached a record high in the third quarter of 2025, representing a 95% increase over the previous quarter. The increase reflects growing adoption by Veterans hospitals and market expansion in the mid-Atlantic region.
• Primarily as a result of the Company's targeted strategic actions to discontinue certain unprofitable pathology services, reduce costs through operational efficiency, and drive sales growth for CyPath Lung, consolidated revenue decreased approximately 36%.

Industry Context

BioAffinity Technologies operates in the highly competitive and regulated medical diagnostics and biotechnology sectors, focusing on early lung cancer detection, COPD, asthma diagnostics, and cancer therapeutics. The increase in CyPath Lung sales, particularly in Veterans hospitals, suggests a growing market acceptance for non-invasive early detection methods. The company's strategic shift away from unprofitable pathology services aligns with a broader industry trend of companies focusing on core, high-growth, and high-margin product lines. The pursuit of AI-driven diagnostics and novel therapeutic approaches positions it within cutting-edge areas of medical innovation.

Comparison to Industry Standards

• The company's CyPath Lung test, detecting lung cancer at Stage 1A, offers a 95% 10-year survival rate, significantly higher than the current overall 5-year survival rate of 26% (according to a NEJM study), indicating a potentially superior diagnostic capability compared to existing methods.
• The company's focus on non-invasive precision diagnostic tests for asthma and COPD, designed to detect specific receptors, aims to address a critical need for personalized medicine in these areas, where current therapies are effective for some but not all patients.
• The company's accumulated deficit of $65.4 million and ongoing "going concern" warning are common for early-stage biotechnology companies heavily invested in R&D and clinical trials, but it highlights the significant capital requirements and inherent risks in this industry.

Management Changes

Corporate Governance

Legal Proceedings

• No material pending legal proceedings or litigation matters that are expected to have a material adverse impact on financial position or results of operations.

Related Party Transactions

• No disclosed related party dealings.

Stakeholder Impact

• Shareholders: Significant dilution from recent and planned capital raises, but improved liquidity and Nasdaq compliance reduce immediate delisting risk. Continued losses and going concern warning pose ongoing investment risk.
• Employees: Addition of personnel to support CyPath Lung sales, but strategic actions to reduce costs in lab operations may imply some workforce adjustments in other areas.
• Customers: Discontinuation of certain unprofitable pathology services may affect some existing customers, while increased focus on CyPath Lung aims to improve service for lung cancer diagnostic patients.
• Creditors: Improved cash position from recent financings may reduce immediate credit risk, but the going concern warning indicates long-term solvency challenges.

Next Steps

• Continue development of flow cytometry platform for diagnostic tests targeted at COPD and asthma.
• Advance research and development for therapeutic discoveries, starting with topical treatment for squamous cell skin cancer.
• Present findings at conferences and publish research in peer-reviewed journals for therapeutic discoveries.
• Seek strategic partners to develop therapeutic discoveries.
• Raise further capital through equity or debt securities, strategic relationships, or grants to support future operations.
• Maintain compliance with Nasdaq listing requirements during the one-year mandatory panel monitor period.
• Expand commercialization efforts for CyPath Lung.

Key Dates

Recommendation

The company presents a mixed bag of results. On one hand, the significant growth in CyPath Lung revenue and successful resolution of Nasdaq compliance issues are strong positives, indicating progress in its core diagnostic product and maintaining market access. The recent capital raises have also bolstered liquidity, extending the cash runway. However, the overall financial picture remains challenging with a widening net loss, a substantial accumulated deficit, and an explicit "going concern" warning from management and auditors. The strategic shift to discontinue unprofitable services is a necessary step but has contributed to overall revenue decline. Given the high-risk nature of early-stage biotech, the ongoing need for capital, and the inherent uncertainties in clinical development and market adoption, a "hold" recommendation is appropriate. Investors should monitor the company's ability to sustain CyPath Lung growth, manage its cash burn, and secure additional funding without excessive dilution, while also watching for progress in its clinical trials and therapeutic pipeline. The one-year Nasdaq monitoring period also adds a layer of caution.

Keywords

bioAffinity Technologies, BIAF, 10-Q, lung cancer diagnosis, CyPath Lung, flow cytometry, AI diagnostics, biotechnology, medical devices, clinical trials, cancer therapeutics, Nasdaq compliance, capital raise, going concern, financial results, Q3 2025, patent, corporate governance